Kidney Failure, Acute Clinical Trial
Official title:
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery for Renal Mass Excision: Assessment by Ischemia Biomarkers, NGAL, KIM-1
Based on animal studies, it was found that administration of endothelial receptor antagonists
before and after renal blood vessels clamp and release results in a significantly reduced
renal function injury.
On the basis of these results, we chose to divide the study population into 2 groups: control
group that would be treated the standard accepted preventive treatment: intravenous injection
of Mannitol, cooling of the kidney surface, compared to the treatment group that in addition
would receive pre- and post-operative treatment of endothelial receptor antagonists
(Ambrisentan (Volibris (10mg).
To be noticed that the drug is recognized and is given as a primary indication for patients
with pulmonary hypertension.
The differences between the renal function and biomarkers for pre- and post-operative renal
ischemic injury would be examined in order to disclose if the kidney injury of the treated
group was indeed smaller.
This information will enable us to protect the operated kidneys from the ischemic damage,
especially in those patients with poor basic renal function.
This is a study aimed at examining the protective effect of endothelin antagonism on the
ischemic damage the kidney undergoes during partial nephrectomy for kidney lesion removal.
In such procedure, it is common to clamp the kidney blood vessels in order to eliminate blood
flow in the surgical field that will enable clear visibility to differentiate the tumor
tissue from the normally kidney parenchyma.
Later, after removing the tumor lesion and suturing the tumor bed, the blockage is released
and the renal blood flow returns.
The blockage itself and its release causes damage to the kidney tissue that is usually
reduced by the kidney's cooling (through ice crystals)and as well as intravenous injection of
mannitol.
In this study, patients were divided into 2 groups randomly, assigned the receipt in the
order of recruitment.
The first group will receive the standard treatment and the other will be given before and
after surgery endothelin antagonists in addition to the standard treatment. The drug will be
given once a day for 5 days, starting 48 hours before surgery. Treatment efficacy assessment
will be based on comparison of renal function (serum creatinine level and glomerular
filtration) as well as biomarkers of acute renal damage (NGAL, KIM-1, and others) that will
be taken from patients before and at different time points after surgery: urine samples to be
taken at the following time points: - 3 , 8,24,48,72 hours after surgery. Blood samples will
be taken at the following time points: - 8, 24, 48, 72 hours after surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00982527 -
Fenoldopam in Pediatric Cardiac Surgery
|
Phase 3 | |
| Completed |
NCT00908843 -
Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration
|
N/A | |
| Completed |
NCT00654992 -
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT05407272 -
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
|
N/A | |
| Not yet recruiting |
NCT05399420 -
Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure
|
||
| Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
| Completed |
NCT04072432 -
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT00230412 -
Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)
|
N/A | |
| Completed |
NCT00148044 -
Uremic Toxins of Patients With Acute Kidney Failure
|
N/A | |
| Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
| Completed |
NCT03353389 -
Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
|
||
| Completed |
NCT03727581 -
Ultrasound for Guidewire Detection
|
||
| Completed |
NCT00912184 -
Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00522756 -
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy
|
Phase 3 | |
| Terminated |
NCT00316576 -
Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)
|
N/A | |
| Completed |
NCT00484354 -
Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
|
Phase 2 | |
| Completed |
NCT00122018 -
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
|
Phase 2 | |
| Unknown status |
NCT01359722 -
N-acetylcysteine to Prevent Renal Failure
|
N/A | |
| Completed |
NCT00286273 -
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
|
Phase 4 | |
| Completed |
NCT03476460 -
Sodium Chloride and Contrast Nephropathy
|
Phase 2 |